We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2.

Nov 20, 2020 · The blocking potency of IgYs on the SARS-CoV-2 pseudovirus was evaluated by luciferase-generated luminescence. Here, Hela monoclonal cells with overexpressed ACE2 were infected with the lentivirus carrying SARS-CoV-2 spike protein and the luciferase reporter gene (GenScript Co., Nanjing, China).

Dec 22, 2022 · In this study, we addressed the use of passive chicken neutralizing IgY-polyclonal antibodies (N-IgY-pAb), since the novel N-IgY-pAb and its “intranasal spray” neutralized the wild type of SARS-CoV-2 (“‘WH-Human 1”) and variants of Delta and Omicron up to 98%.

Feb 23, 2022 · A new study posted to the bioRxiv* preprint server reports on the development of anti-RBD immunoglobulin Y (IgY) antibodies from chicken eggs to block the binding of the viral RBD to human ACE2...

Feb 21, 2022 · We have developed anti-RBD IgY antibodies from chicken eggs by immunizing the birds with RBD domain of SarsCov2 spike protein as a strategy to block the binding of virus RBD to human ACE2 receptors.

IgY targeting S1 subunit of SARS‐CoV‐2 could be a promising candidate for pre‐ and post‐exposure prophylaxis or treatment of COVID‐19. Administration of IgY‐based oral preparation, oral or nasal spray may have profound implications for blocking SARS‐CoV‐2.

We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2.

Feb 22, 2022 · Towards this unmet need we have developed chicken egg derived anti-RBD IgY antibodies that neutralize the binding of Omicron RBD to human ACE2. Furthermore, we have formulated the edible IgY as flavored beverages to allow for use as oral rinse and prevent the entry of Omicron in the oropharyngeal passage, a major access and accumulation point ...

Feb 16, 2021 · S-IgY can inhibit the entry and replication of SARS-CoV-2, which is related to its targeting the ACE2 binding domain. S-IgY is safe, efficient, stable and easy to obtain. This antibody may have the potential to be an effective method for the prevention and treatment of COVID-19 pneumonia.

Our study aimed to evaluate the neutralizing potential of specific IgY targeting S1, receptor-binding-domain (RBD) of spike glycoprotein and nucleocapsid (N) of SARS-CoV-2 to inhibit RBD and angiotensin-converting-enzyme-2 (ACE2) binding interaction.